Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Smith-Magenis Syndrome, Circadian
Interventions: tasimelteon, placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 3 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Santa Monica, California • Baltimore, Maryland • Chevy Chase, Maryland + 1 more

Conditions: Renal Anemia
Interventions: AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars; Drug
Lead sponsor: Kind Pharmaceuticals LLC; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Pine Bluff, Arkansas • Riverside, California • Lone Tree, Colorado + 5 more

Conditions: Sleep Apnea, Obstructive
Interventions: Seltorexant 40 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Prostate Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertriglyceridemia
Interventions: Docosahexenoic acid (DHA), Olive oil; Dietary Supplement
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 39 Years to 66 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Davis, California

Conditions: Enteric Hyperoxaluria, Primary Hyperoxaluria, Hyperoxalemia
Interventions: ALLN-177; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 1 more

Conditions: Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions: ANS014004 + PLB1004, ANS014004 + Osimertinib; Drug
Lead sponsor: Beijing Pearl Biotechnology Limited Liability Company; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Obsessive-Compulsive Disorder
Interventions: Nabilone, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: EBV Viremia, CMV Viremia
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acne
Interventions: 100% cocoa powder, gelatin (Gelita); Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus
Interventions: Pioglitazone, Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: TAS-114, S-1; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Loma Linda, California • Gainesville, Florida • Cleveland, Ohio + 3 more

Conditions: Constipation
Interventions: Vibrating Capsule, Sham capsule; Device
Lead sponsor: Vibrant Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Canoga Park, California • Albuquerque, New Mexico • Willoughby, Ohio + 1 more

Conditions: Diabetes
Interventions: placebo, Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15), Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5); Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 40
States / cities: Muscle Shoals, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 35 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 69
States / cities: Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more

Conditions: Healthy
Interventions: Midazolam Alone, Qualaquin (quinine) alone steady state, Midazolam and Qualaquin at steady state; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Chronic Inflammation, Overweight
Interventions: Placebo, Palmitoleic acid, 500 mg (Dose 1), Palmitoleic acid, 1,000 mg (Dose 2); Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Cocaine Dependence
Interventions: Doxazosin, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer Disease
Interventions: ASN51, Placebo; Drug
Lead sponsor: Asceneuron S.A.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 7
States / cities: Clermont, Florida • Lady Lake, Florida • Maitland, Florida + 4 more

Conditions: Hair Thinning, Hair Shedding
Interventions: Scale HLV Clinical Formula Hair Vitamins, Placebo; Dietary Supplement · Other
Lead sponsor: Scale Media Inc; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Stanford, California + 6 more

Conditions: Neoplasm Malignant
Interventions: Pembrolizumab, Belzutifan, Lenvatinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 13 more

Conditions: Central Neuropathic Pain, Multiple Sclerosis
Interventions: AVP-923-45, AVP-923-30, AVP-923-20, Placebo; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 44
States / cities: Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more

Conditions: Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Interventions: Lenalidomide, Dexamethasone, Rituximab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes

Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Drug-Drug Interaction Study of Qualaquin and Midazolam

Effect of Palmitoleic Acid on C-reactive Protein

Pharmacogenetics of Doxazosin for Cocaine Dependence

Study of ASN51 in Adults With Early Alzheimer's Disease

A Clinical Trial to Examine the Efficacy of a Dietary Supplement to Improve the Health and Appearance of Hair.

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas